The scale of the competition behind this year’s prizes underscores how coveted the awards have become. The 2026 Laureates were selected from a pool of 372 nominees representing 187 academic and research institutions across 43 states. From that national field, an independent jury of eminent scientists chose three winners and 15 Finalists, each of whom received $15,000 in unrestricted funding. Nine honorees of the Blavatnik Regional Awards were also recognized during the evening. For two institutions the night carried special significance: The Ohio State University and the Arc Institute each celebrated their first-ever Blavatnik National Award Laureate, a milestone that signals how the geography of elite early-career research continues to broaden beyond the usual constellation of coastal institutions.

In the chemical sciences, the Laureate is David Nagib, an organic chemist tackling one of the most persistent bottlenecks in medicine: the sheer difficulty of synthesizing complex molecules. Organic synthesis often determines how quickly a promising drug candidate can be made, tested, and improved, and Nagib’s laboratory has focused on harnessing two of chemistry’s most reactive and unruly species, radicals and carbenes, to forge key medicinal building blocks. Radicals and carbenes are notoriously energetic intermediates, capable of transforming molecules in ways that gentler reagents cannot, but historically difficult to control. Nagib’s group has invented methods to activate portions of complex molecules that were previously considered inert, effectively unlocking chemical real estate that synthetic chemists had long been unable to reach.

The significance of that achievement lies in reliability. By converting high-energy chemistry into dependable, reproducible methods, Nagib’s work allows chemists to create more potent and selective medicines faster, cheaper, and more efficiently than conventional routes permit. In practical terms, that means medicinal chemists can explore a wider swath of chemical space when hunting for new drugs, attaching or rearranging molecular features that were once off-limits. The advances are already accelerating pharmaceutical discovery and expanding the boundaries of what modern organic chemistry can accomplish, a contribution the Blavatnik jury singled out in naming him the Chemical Sciences Laureate.

In the life sciences, the Laureate is Patrick Hsu, a bioengineer and co-founder of the Arc Institute whose work sits at the frontier of genome engineering. Biology depends on molecular machines that read, write, and regulate genetic information, and Hsu’s laboratory discovers and engineers these programmable systems to manipulate DNA and RNA with precision. His contributions have widened the CRISPR toolkit with RNA-targeting enzymes, extending gene-editing capability beyond DNA to the transcriptome. More striking still, his team uncovered programmable bridge RNAs, molecules that can direct large-scale genome rewriting by physically bridging a target DNA site with a donor sequence, a mechanism that hints at edits far more ambitious than the small cuts and swaps of first-generation CRISPR tools.

Hsu has also pushed genome engineering into the age of artificial intelligence, pioneering AI models that predict and design biological sequences. Together, these innovations are transforming how scientists approach genome engineering, accelerating biological discovery, and supporting the development of new gene therapies. The Blavatnik citation describes the work as laying the foundation for a new era of AI-enabled biological design, in which computational models and programmable molecular machines work in tandem to rewrite the instructions of life. The recognition is equally a landmark for the Arc Institute, the young Palo Alto research organization Hsu co-founded, which now counts its first Blavatnik National Award Laureate among its ranks.

The Physical Sciences and Engineering Laureate, Jonathan Rivnay, works on a problem that sounds deceptively simple: the human body runs on chemical and ionic signals, but ordinary electronics struggle to read them, let alone join the conversation. A materials scientist and biomedical engineer, Rivnay designs soft, flexible electronic materials that can interface directly with living cells and tissue, bridging the gap between the wet, ionic world of biology and the electronic world of silicon. His devices must conduct ions as well as electrons, bend without breaking, and operate safely within the body, a set of constraints that has driven much of the field of organic bioelectronics in which he has become a leading figure.

Among Rivnay’s most ambitious contributions are implantable devices he helped pioneer known as living pharmacies. These small implants hold engineered cells and prompt them to manufacture and release medicines inside the body, effectively turning a patient’s own therapeutic cells into a controlled drug factory. The approach points toward more personalized treatments for long-term conditions such as cancer, diabetes, and circadian rhythm disorders, diseases in which dosing needs fluctuate and conventional drugs often fall short. By combining flexible electronics with living cells, Rivnay’s research suggests a future in which therapy is delivered on demand, in place, and in tune with the body’s own signals.

The evening was also an occasion for reflection on what two decades of early-career recognition can produce. Lifton, presenting the awards, traced the trajectory of the inaugural cohort of 14 honorees recognized twenty years earlier. Eight of them now hold named and endowed chairs at institutions including Yale, Rockefeller, Cornell, Columbia, and Cambridge. Five have been elected to the U.S. National Academy of Sciences, two to the National Academy of Medicine, six to the American Academy of Arts and Sciences, and one to the Royal Society of the UK. Subsequent to their Blavatnik Awards, members of that first group have won prizes including the Shaw Prize, the Benjamin Franklin Medal, and the Fields Medal, a record that lends weight to the program’s central bet on identifying talent early.

That bet has a well-documented origin story. Nicholas B. Dirks, President and CEO of The New York Academy of Sciences and Chair of the Awards’ Scientific Advisory Council, recalled in his remarks that the idea was inspired by Len Blavatnik’s experience at the 2007 Nobel Prize ceremony, where the prestige of honoring lifelong discoveries prompted a question: what if exceptional scientists could be recognized earlier in their careers, at a pivotal moment when they were just beginning to build their own research programs, pursue ambitious scientific questions, and take creative risks. The Blavatnik Awards were born as a first-of-its-kind science prize dedicated to the most promising early-career scientists of their generation. Since 2007 the program has honored 539 scientists and awarded $21.5 million in unrestricted funding, and it now spans the United States, the United Kingdom, and Israel, awarding more than $2 million annually. At a time when intense competition for research funding makes it increasingly difficult for young investigators to establish independent programs, unrestricted prize money gives recipients freedom to pursue high-risk, high-reward research that conventional grants often cannot support. The economic ripple effects are tangible as well: Blavatnik honorees to date have founded 52 companies, six of them publicly traded, collectively valued at more than $40 billion, evidence that early recognition of scientific talent can translate into discoveries, therapies, and industries that reach far beyond the laboratory.

Subject of Research: The 2026 Blavatnik Awards for Young Scientists honoring early-career research in organic chemistry, genome engineering and bioelectronics

Article Title: Three scientists honored with $250,000 Blavatnik Awards for breakthroughs in organic chemistry, gene editing and bioelectronics

Article References: Three scientists honored with $250,000 Blavatnik Awards for breakthroughs in organic chemistry, gene editing and bioelectronics. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Blavatnik Awards, David Nagib, Patrick Hsu, Jonathan Rivnay, organic chemistry, CRISPR, bridge RNAs, genome engineering, bioelectronics, living pharmacies, New York Academy of Sciences, early-career scientists

The foundations of this transformation are already established in the clinic. Liposomal doxorubicin and albumin-bound paclitaxel became FDA-approved cancer therapeutics decades ago, improving tolerability and therapeutic index for patients. The decisive proof of concept, however, came with the lipid nanoparticle platforms that enabled the rapid development and global deployment of mRNA vaccines against SARS-CoV-2. According to the authors, these milestones demonstrate not only that nanomedicine works, but that nanoscale engineering can accelerate the translation of advanced therapeutics, reshape response profiles, reduce toxicity and make molecular modalities previously infeasible in vivo a practical reality.

One of the most striking frontiers described in the perspective is the use of living cells as delivery vehicles. Rather than fighting the body’s biological barriers with synthetic materials alone, researchers are now exploiting them. Nanoparticles can hitchhike on red blood cells, dramatically reducing clearance by the liver and spleen while extending circulation time, and in some designs depositing their cargo preferentially in the lungs through contact-mediated dislodging from the cell surface. Discoidal polymer particles known as cellular backpacks ride on macrophages, monocytes, T cells, neutrophils and B cells, modulating immune cell behavior in applications ranging from cancer to multiple sclerosis and traumatic brain injury. These hybrid systems combine the precision of engineered materials with the navigation skills of the body’s own cells.

Immunology is emerging as a central arena for this new generation of nanotechnologies. Cell membrane–coated nanoparticles, or CNPs, wrap synthetic cores in natural cellular membranes, presenting native antigen repertoires that conventional vaccines struggle to replicate. Cancer cell membrane–coated particles elicit potent antitumor immunity, while bacterial outer membrane vesicle platforms preserve pathogen-associated molecular patterns to generate broad-spectrum protection, including against antimicrobial-resistant strains. Nanotoxoids take this further, detaining bacterial toxins on nanoparticle surfaces so the immune system can safely learn their shapes. Advances in membrane genetic engineering and modular linker chemistry are now turning these platforms into rapidly customizable, scalable vaccine systems.

Perhaps the most futuristic concept described is the living pharmacy: implanted, encapsulated cells that continuously manufacture biologics inside the body. The recent FDA approval of Neurotech’s ENCELTO, an encapsulated allogeneic cell therapy implanted in the eye, anchors the feasibility of the approach. Modern platforms combine synthetic biology programs that control what cells produce, biomaterials that tame the foreign body response while allowing oxygen and nutrient exchange, and device interfaces offering retrievability and external control, including electro- and optogenetic actuation. Key challenges ahead include improving volumetric efficiency, ensuring predictable dosing behavior and demonstrating durable performance in large-animal models.

On the cancer front, the perspective highlights how macrophages, long viewed as obstacles that clear nanoparticles from circulation, are being reprogrammed into therapeutic partners. Ultrasound-guided platforms deliver STING agonists directly to antigen-presenting cells, while constructs that disrupt the CD47 ‘don’t eat me’ signal enable macrophage-mediated tumor cell phagocytosis. Blocking the MARCO receptor reduces hepatic sequestration of nanoparticles, boosting tumor accumulation. In hypovascularized breast cancer liver metastases, redirecting albumin-bound paclitaxel transport toward macrophages significantly improves therapeutic outcomes in a setting where conventional intravenous delivery largely fails. Implantable nanofluidic drug-eluting seeds add another layer of control, sustaining localized intratumoral immunotherapy for more than four weeks and converting immunologically cold tumors into hot ones at a fraction of the systemic dose.

Polymer chemistry is advancing carrier performance in parallel. Poly(2-oxazoline) and poly(2-oxazine) micelles achieve drug loads ten to one hundred times higher than traditional micelles, enabling intravenous formulations with minimal excipient content. The first POx-based medical product, a hemostatic sealing patch, received European approval in 2023, and the absence of preexisting anti-POx antibodies makes these polymers attractive alternatives to polyethylene glycol, which is increasingly associated with immunogenicity. Vascular-confined discoidal nanoconstructs carrying tissue plasminogen activator, meanwhile, recanalize roughly ninety percent of occluded venules in mouse models compared with about forty percent for free tPA, while preserving neurological outcomes and improving survival in stroke models.

Gene and RNA nanotherapies represent another pillar of the expanded field. In vivo CRISPR delivery via lipid nanoparticles aims to democratize access to genetic cures, bypassing the roughly 2.2 million dollar per patient cost of autologous ex vivo editing. Mesoscale nanoparticles of 300 to 500 nanometers selectively target the renal proximal tubule, delivering siRNAs and mRNAs for kidney diseases that have historically been inaccessible to systemic RNA therapeutics. In the liver, a strategy termed Repair Drive uses transient siRNA inhibition of an essential gene to eliminate unedited hepatocytes, expanding precisely corrected cells from less than one percent to approximately twenty-five percent of the liver. Transient telomerase mRNA delivered by lipid nanoparticles is showing promise for protecting skin from radiation-induced DNA damage, operating through genome and mitochondrial maintenance rather than telomere extension.

The perspective also documents a radical extension of the concept: therapeutics built from organelles and biological vesicles themselves. Extracellular vesicles from brain endothelial cells carry functional mitochondria and, when administered intravenously after stroke in mice, significantly reduce brain infarct volume and improve neurological function. Exogenous mitochondrial transfer into plaque macrophages reduces atherosclerotic burden and improves markers of fatty liver disease, positioning mitochondrial transplantation as an emerging metabolic nanotherapy. Hybrid vesicles that merge extracellular vesicle targeting with synthetic liposome stability offer enhanced tumor accumulation with improved scalability over native EV preparations.

The authors close with a vision of a modular nanomedicine ecosystem in which nanoparticles behave like cells, cells function as therapeutic devices, devices operate as immunomodulators, and imaging technologies evolve into pharmacologic tools. Realizing that vision, they emphasize, will require manufacturing and quality-by-design frameworks that embed reproducibility, safety and scalability from the outset, translating laboratory ingenuity into clinical-grade platforms capable of sensing, computing and responding to disease in real time.

Subject of Research: The expansion of nanomedicine beyond drug carriers into implantable devices, cell-based systems and living therapeutics

Article Title: Nanomedicine beyond carriers — devices, cells & living therapeutics

Article References: Grattoni, A., Paci, M. M., Arnold, N., Aryal, S., Artzi, N., Bao, G., Barcena, A. J. R., Bentov-Arava, E., Blanco, E., Chua, C. Y. X., Corradetti, B., Cryer, A. M., Decuzzi, P., De Giorgi, M., Fell, C., Gao, W., Govindaswamy, B., Jiang, W., Kara, G., … Godin, B. (2026). Nanomedicine beyond carriers — devices, cells & living therapeutics. Biomedical Microdevices, 28(3), Article 65. https://doi.org/10.1007/s10544-026-00836-8

Image Credits: AI Generated

DOI: 10.1007/s10544-026-00836-8

Keywords: nanomedicine, drug delivery, lipid nanoparticles, mRNA vaccines, cell membrane-coated nanoparticles, immunotherapy, living pharmacies, CRISPR, extracellular vesicles, mitochondrial transfer, nanofluidic implants, poly(2-oxazoline)